Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares

Rhea-AI Filing Summary

Mineralys Therapeutics files a Form 144 reporting proposed sales of 75,000 shares of Common Stock. The filing lists an aggregate offering price of $1,970,520.69 and notes total shares outstanding of 82,399,478 as of 03/31/2026. It also discloses recent vesting of restricted share units (63,665 and 11,335 shares) and a related sale by Jon Congleton of 16,236 shares on 01/12/2026 for $529,639.51.

Insights

Securities Compliance Analyst

Form 144 notifies the broker and SEC of intended affiliate sales; quantities and prices are disclosed.

Form 144 is a regulatory notice that brokers file when affiliates plan restricted or control stock sales. The filing here specifies 75,000 shares proposed and an aggregate offering price of $1,970,520.69, which aligns with typical disclosure requirements for planned dispositions.

Timing and methods of sale are not detailed in the excerpt; subsequent trade notices or broker reports will show actual execution details and any impact on public float.

Key Figures

Proposed shares to sell: 75,000 shares Aggregate offering price: $1,970,520.69 Shares outstanding: 82,399,478 shares +3 more

6 metrics

Proposed shares to sell 75,000 shares Form 144 securities summary

Aggregate offering price $1,970,520.69 Form 144 securities summary

Shares outstanding 82,399,478 shares as of 03/31/2026

Recent sale by Jon Congleton 16,236 shares sold on 01/12/2026 for $529,639.51

RSU vesting — 06/10/2024 63,665 shares Vesting of restricted share unit award

RSU vesting — 07/10/2024 11,335 shares Vesting of restricted share unit award

Key Terms

restricted share unit, Form 144, aggregate offering price

3 terms

restricted share unit financial

"Vesting of restricted share unit award"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

aggregate offering price financial

"Merrill Lynch ... | 1970520.69"

The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	75000	1970520.69	82399478	03/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/10/2024	Vesting of restricted share unit award	Mineralys Therapeutics, Inc.			63665	06/10/2024	Granted as part of issuer equity compensation plan
Common Stock	07/10/2024	Vesting of restricted share unit award	Mineralys Therapeutics, Inc.			11335	07/10/2024	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jon Congleton 150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PA 19087	Common Stock	01/12/2026	16236	529639.51

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Mineralys Therapeutics (MLYS) Form 144 report?

It reports a proposed sale of 75,000 shares of common stock with an aggregate price of $1,970,520.69. The filing also lists vested RSUs and a recent sale of 16,236 shares by Jon Congleton on 01/12/2026.

Who is the selling party referenced in the MLYS Form 144?

The filing names a broker (Merrill Lynch) and shows an affiliated seller associated with the notice. It separately records a sale by Jon Congleton of 16,236 shares on 01/12/2026.

How many Mineralys shares are outstanding as shown in the filing?

The filing lists 82,399,478 shares outstanding as of 03/31/2026. This figure is presented in the securities summary alongside the proposed offering quantity and price.

Does the Form 144 show recent equity awards for MLYS insiders?

Yes; it records vesting of restricted share unit awards totaling 63,665 and 11,335 shares with vesting dates 06/10/2024 and 07/10/2024, respectively, granted under the issuer's equity compensation plan.